Ginkgo Bioworks Holdings (DNA) Common Equity (2019 - 2026)

Ginkgo Bioworks Holdings' Common Equity history runs 8 years deep, the most recent figure standing at $443.2 million for Q1 2026.

• Quarterly Common Equity fell 31.55% year-over-year to $443.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $443.2 million (down 31.55% YoY) and the FY2025 annual result came in at $508.6 million, down 28.97% from the prior year.
• Common Equity was $443.2 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $508.6 million in the prior quarter.
• Across five years, Common Equity topped out at $1.7 billion in Q4 2022 and bottomed at $443.2 million in Q1 2026.
• A 5-year average of $1.1 billion and a median of $987.3 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity jumped 341.91% — and 2024, when it plunged 44.59%.
• Ginkgo Bioworks Holdings' Common Equity stood at $1.7 billion in 2022, then sank by 36.81% to $1.1 billion in 2023, then tumbled by 34.73% to $716.1 million in 2024, then slipped by 28.97% to $508.6 million in 2025, then declined by 12.87% to $443.2 million in 2026.
• Business Quant data shows DNA's Common Equity at $443.2 million in Q1 2026, $508.6 million in Q4 2025, and $559.8 million in Q3 2025.